ValiRx, a life science company focussed on early-stage cancer therapeutics and women's health, announced the first sale from its wholly-owned subsidiary Inaphaea BioLabs on Monday.
Valirx
18 November 2024 14:04:39
Source: Sharecast
The AIM-traded firm said the shipment included patient-derived cells (PDCs), part of Inaphaea’s new Assay Ready Reagents (ARR) product line.
It said the ARR range allowed customers to perform assays directly without requiring in-house cell cultivation, streamlining research workflows.
While the financial value of the initial order was said to not be material, the board said the sale represented a key milestone in validating Inaphaea’s offering and providing a potential revenue stream for ValiRx.
“This first sale of our new product range is a major milestone for our commercialisation efforts,” said chief executive officer Mark Eccleston.
At 1158 GMT, shares in ValiRx were up 23.13% at 1.69p.
Reporting by Josh White for Sharecast.com.
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
